Quantitative analysis of the effect of docetaxel-induced edema on quality of life in patients with breast cancer and related factors: a prospective cohort study.
Bioimpedance analysis
Breast cancer
Docetaxel
Quality of life
Systemic edema
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
07 Mar 2024
07 Mar 2024
Historique:
received:
06
09
2023
accepted:
28
02
2024
medline:
8
3
2024
pubmed:
8
3
2024
entrez:
8
3
2024
Statut:
epublish
Résumé
Systemic edema is an adverse effect of docetaxel chemotherapy and causes distress to patients, including those receiving this agent for breast cancer. However, its characteristics and factors related to its effect on quality of life (QoL) have not been adequately investigated. In this study, we assessed systemic edema quantitatively, explored related factors, and evaluated QoL in patients receiving docetaxel for breast cancer. The study had a prospective cohort design and included 37 patients with no known history of swelling who were treated with docetaxel between September 2019 and April 2022. Patients were examined at the start, middle, and end of their course of treatment and 1 and 2 months later. Body water content, body mass, fat mass, and muscle mass were quantified using bioelectrical impedance analysis. Systemic edema was evaluated with reference to the Common Terminology Criteria for Adverse Events. The timing of development of systemic edema at any anatomical site that was grade 2 or worse was recorded. QoL was assessed using the Quality of Life-Anti Cancer Drug scale. Nutrition was evaluated using the Brief-type self-administered diet history questionnaire. Multivariable logistic regression analysis was performed to identify related factors. QoL was also compared between patients with edema and those without edema. Systemic edema developed in 67% of the study participants and was most prevalent at the end of treatment. Body fat mass (adjusted odds ratio [aOR] 0.802, 95% confidence interval [CI] 0.651-0.988, p = 0.038), disease stage (aOR 3.279, 95% CI 0.493-21.793, p = 0.219), and history of alcohol consumption (aOR 0.141, 95% CI 0.013-1.521, p = 0.106) were identified as risk factors for docetaxel-induced edema. Participants who developed systemic edema experienced more physical, vital, and emotional distress 1 month after treatment than those who did not. There was no association between systemic edema and nutrition. Systemic edema may develop after treatment with docetaxel and increase distress in patients with a high body fat mass. Patients at risk of systemic edema should be informed in advance about the potential frequency, location, and timing of its onset and encouraged to self-manage this condition.
Sections du résumé
BACKGROUND
BACKGROUND
Systemic edema is an adverse effect of docetaxel chemotherapy and causes distress to patients, including those receiving this agent for breast cancer. However, its characteristics and factors related to its effect on quality of life (QoL) have not been adequately investigated. In this study, we assessed systemic edema quantitatively, explored related factors, and evaluated QoL in patients receiving docetaxel for breast cancer.
METHODS
METHODS
The study had a prospective cohort design and included 37 patients with no known history of swelling who were treated with docetaxel between September 2019 and April 2022. Patients were examined at the start, middle, and end of their course of treatment and 1 and 2 months later. Body water content, body mass, fat mass, and muscle mass were quantified using bioelectrical impedance analysis. Systemic edema was evaluated with reference to the Common Terminology Criteria for Adverse Events. The timing of development of systemic edema at any anatomical site that was grade 2 or worse was recorded. QoL was assessed using the Quality of Life-Anti Cancer Drug scale. Nutrition was evaluated using the Brief-type self-administered diet history questionnaire. Multivariable logistic regression analysis was performed to identify related factors. QoL was also compared between patients with edema and those without edema.
RESULTS
RESULTS
Systemic edema developed in 67% of the study participants and was most prevalent at the end of treatment. Body fat mass (adjusted odds ratio [aOR] 0.802, 95% confidence interval [CI] 0.651-0.988, p = 0.038), disease stage (aOR 3.279, 95% CI 0.493-21.793, p = 0.219), and history of alcohol consumption (aOR 0.141, 95% CI 0.013-1.521, p = 0.106) were identified as risk factors for docetaxel-induced edema. Participants who developed systemic edema experienced more physical, vital, and emotional distress 1 month after treatment than those who did not. There was no association between systemic edema and nutrition.
CONCLUSIONS
CONCLUSIONS
Systemic edema may develop after treatment with docetaxel and increase distress in patients with a high body fat mass. Patients at risk of systemic edema should be informed in advance about the potential frequency, location, and timing of its onset and encouraged to self-manage this condition.
Identifiants
pubmed: 38454375
doi: 10.1186/s12905-024-03003-4
pii: 10.1186/s12905-024-03003-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
165Subventions
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP22K10868
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Organisme : Japan Society for the Promotion of Science KAKENHI
ID : JP19K10926
Informations de copyright
© 2024. The Author(s).
Références
Willson ML, Burke L, Ferguson T, Ghersi D, Nowak AK, Wilcken N. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev. 2019;9:CD004421.
Japanese Breast Cancer Society. Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer. Tokyo: Kanehara Publishing; 2002.
Andersson M, Lidbrink E, Bjerre K, Wist E, Enevoldsen K, Anders B, et al. Phase III randomized study comparing docetaxel plus trantumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor 2-positive breast cancer: the HERNATA study. J Clin Oncol. 2011;29:264–71. https://doi.org/10.1200/JCO.2010.30.8213 .
doi: 10.1200/JCO.2010.30.8213
Roché H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS01 trial. J Clin Oncol. 2006;24:5664–71. https://doi.org/10.1200/JCO.2006.07.3916 .
doi: 10.1200/JCO.2006.07.3916
Ohsumi S, Shimozuma K, Ohashi Y, Takeuchi A, Suemasu K, Kuranami M, et al. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: the National Surgical Adjuvant Study of Breast Cancer 02. Oncology. 2012;82:131–8. https://doi.org/10.1159/000336480 .
doi: 10.1159/000336480
Brønstad A, Berg A, Reed RK. Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure. Am J Physiol Heart Circ Physiol. 2004;287:H963–8. https://doi.org/10.1152/ajpheart.01052.2003 .
doi: 10.1152/ajpheart.01052.2003
Wamsteker WH, Robbeson C, Nijs J, Hoelen W, Meeus M. The effect of docetaxel on developing oedema in patients with breast cancer: a systematic review. Eur J Cancer Care. 2016;25:269–79. https://doi.org/10.1111/ecc.12261 .
doi: 10.1111/ecc.12261
Japan Lymphedema Study Group. Prevention and treatment. In: Group JLS, editor. Lymphoedema Clinical Practice Guidelines. Tokyo: Kanehara Publishing; 2018. p. 18–28 [in Japanese].
Izawa T. Treatment and care of edema caused by taxane anticancer agents. Japanese Society for Lymphedema Therapy. 2021;4:38–41.
Hosonaga M, Ito Y, Tokudome N, Takahashi S, Iwase T, Hatake K. A lower dose of docetaxel at 60 mg/m
doi: 10.1007/s12282-011-0297-y
Zhenhua Z, Xiwen Z, Shuntai C, Juling J, Runzhi Q, Xing Z, et al. Taxane-based chemotherapy and risk of breast cancer-related lymphedema: protocol for a systematic review and meta-analysis. Medicine. 2019;98:e16563. https://doi.org/10.1097/MD.0000000000016563 .
doi: 10.1097/MD.0000000000016563
Aoishi Y, Oura S, Nishiguchi H, Hirai Y, Miyasaka M, Kawaji M, et al. Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration. Breast Cancer. 2020;27:929–37. https://doi.org/10.1007/s12282-020-01088-x .
doi: 10.1007/s12282-020-01088-x
Park S, Lee JE, Yu J, Paik H-J, Ryu JM, Kim I, et al. Risk factors affecting breast cancer-related lymphedema: serial body weight change during cyclophosphamide followed by taxane. Clin Breast Cancer. 2018;18:49–54. https://doi.org/10.1016/j.clbc.2017.06.003 .
doi: 10.1016/j.clbc.2017.06.003
Nguyen TT, Hoskin TL, Habermann EB, Cheville AL, Boughey JC. Breast cancer-related lymphedema risk is related to multidisciplinary treatment and not surgery alone: results from a large cohort study. Ann Surg Oncol. 2017;24:2927–80. https://doi.org/10.1245/s10434-017-5960-x .
doi: 10.1245/s10434-017-5960-x
Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev. 2011;37(4):300–11. https://doi.org/10.1016/j.ctrv.2010.11.001 .
doi: 10.1016/j.ctrv.2010.11.001
Ijpma I, Renken RJ, Gietema JA, Slart RHJA, Mensink MGJ, Lefrandt JD, et al. Changes in taste and smell function, dietary intake, food preference, and body composition in testicular cancer patients treated with cisplatin-based chemotherapy. Clin Nutr. 2017;36:1642–8. https://doi.org/10.1016/j.clnu.2016.10.013 .
doi: 10.1016/j.clnu.2016.10.013
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, et al. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Support Care Cancer. 2013;21:549–55. https://doi.org/10.1007/s00520-012-1551-3 .
doi: 10.1007/s00520-012-1551-3
Okuyama H, Nakamura S, Tanaka SA, Sawada T, Kuwayama T, Handa S, et al. QOL evaluation of nab-paclitaxel and docetaxel for early breast cancer. Eur J Breast Health. 2018;14:194–8. https://doi.org/10.5152/ejbh.2018.4174 .
doi: 10.5152/ejbh.2018.4174
pmcid: 6170019
Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, et al. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: current clinical practice. Cancer. 2019;125:2945–54. https://doi.org/10.1002/cncr.32175 .
doi: 10.1002/cncr.32175
Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel plus epirubicin and cyclophosphamide. Acta Oncol. 2012;51:1036–44. https://doi.org/10.3109/0284186X.2012.692884 .
doi: 10.3109/0284186X.2012.692884
Jung GH, Kim JH, Chung MS. Changes in weight, body composition, and physical activity among patients with breast cancer under adjuvant chemotherapy. Eur J Oncol Nurs. 2020;44:101680. https://doi.org/10.1016/j.ejon.2019.101680 .
doi: 10.1016/j.ejon.2019.101680
U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). 2017.
Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, et al. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psycho-Oncol. 1999;8:355–63. https://doi.org/10.1002/(SICI)10991611(199907/08)8:4%3c355::AID-PON401%3e3.0.CO;2-I .
doi: 10.1002/(SICI)10991611(199907/08)8:4<355::AID-PON401>3.0.CO;2-I
Matsumoto T, Ohashi Y, Morita S, et al. The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): Validity and reliability in Japanese patients with advanced non-small-cell lung cancer. Qual Life Res. 2002;11(5):483–93. https://doi.org/10.1023/A:1015614505929 .
doi: 10.1023/A:1015614505929
Lim SM, Han Y, Kim, Park HS. Utilization of bioelectrical impedance analysis for detection of lymphedema in breast cancer survivors: a prospective cross-sectional study. BMC Cancer 2019;19,669. https://doi.org/10.1186/s12885-019-5840-9 .
Kobayashi S, Honda S, Murakami K, Sasaki S, Okubo H, Hirota N, et al. Both comprehensive and brief self-administered diet history questionnaires satisfactorily rank nutrient intakes in Japanese adults. J Epidemiol. 2012;22:151–9. https://doi.org/10.2188/jea.je20110075 .
doi: 10.2188/jea.je20110075
pmcid: 3798594